NASDAQ: PPBTPurple Biotech Ltd Stock
$1.49-0.02 (-1.32%)
Updated Sep 28, 2026
PPBT Price
$1.49
Fair Value Price
$1.76
Market Cap
$3.24M
52 Week Low
$1.16
52 Week High
$14.10
P/E
-0.03x
P/B
0.26x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
$24.49M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.16
Operating Cash Flow
-$8M
Beta
0.59
Next Earnings
Nov 13, 2026
Ex-Dividend
N/A
Next Dividend
N/A
PPBT Overview
Purple Biotech Ltd., a clinical-stage biotechnology firm based in Rehovot, Israel, is dedicated to pioneering treatments that help cancer patients, particularly in the United States, overcome tumor immune evasion and drug resistance. Its pipeline features two primary oncology assets: CM24: A monoclonal antibody designed to block carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1). This candidate is undergoing Phase 1b/2 clinical trials, where it is being evaluated as a combination therapy with anti-PD-1 checkpoint inhibitors for non-small cell lung cancer and pancreatic cancer. NT219: A small molecule compound that targets insulin receptor substrate 1 and 2 (IRS1/2) as well as signal transducer and activator of transcription (STAT) pathways. NT219 is currently in Phase 1/2 clinical studies for the treatment of recurrent or metastatic solid tumors and squamous cell carcinoma of the head and neck. The company was formerly known as Kitov Pharma Ltd until its rebranding to Purple Biotech Ltd. in December 2020.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine PPBT's potential to beat the market
- PPBT doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
PPBT
RankedUnranked of 464
RankedUnranked of 464
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $9.82 | A | |
| $7.81 | A | |
| $367.00 | A |
Be the first to know about important PPBT news, forecast changes, insider trades & much more!
PPBT News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how PPBT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PPBT ($1.49) is undervalued by 15.58% relative to our estimate of its Fair Value price of $1.76 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
PPBT ($1.49) is not significantly undervalued (15.58%) relative to our estimate of its Fair Value price of $1.76 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
PPBT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more PPBT due diligence checks available for Premium users.
Valuation
PPBT fair value
Fair Value of PPBT stock based on Discounted Cash Flow (DCF)
Price
$1.49
Fair Value
$1.76
Undervalued by
15.58%
PPBT ($1.49) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
PPBT ($1.49) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
PPBT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
PPBT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.03x
Industry
15.4x
Market
47.54x
PPBT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.26x
Industry
5.19x
PPBT is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PPBT's financial health
Profit margin
Revenue
$0.0
Net Income
-$441.0k
Profit Margin
0%
PPBT's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$14.2M
Liabilities
$2.0M
Debt to equity
0.16
PPBT's short-term assets ($6.59M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PPBT's short-term assets ($6.59M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PPBT's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
PPBT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.5M
Investing
$1.0k
Financing
$2.1M
PPBT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PPBT vs Biotech Stocks
Purple Biotech Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.